H1 2024 results in-line with expectations
Abivax today reported H12024 results reporting a cash balance at EUR 222.3mn and a cash reach to Q4 2025, thereby reiterating preliminary figures provided last July. The EUR 85.2mn cash used in operation was principally driven by increased R&D spending (EUR 64.7mn) on the Phase III in UC (ABTEC
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.